Skip to main content
  • Saved

Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial

Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial

Source : https://cardiab.biomedcentral.com/articles/10.1186/s12933-019-0965-3

Anagliptin, a dipeptidyl peptidase-4 inhibitor, is reported to reduce the level of low-density lipoprotein cholesterol (LDL-C). The underlying mechanism of this effect and effect on lipid metabolism however remains uncertain. We therefore evaluate the effects of anagliptin on lipid metabolism-related markers compared with those of sitagliptin.

Sign In or Register Today to Access This Content